I'm not surprised that they moved to subscription. But an annual $5000 buy in to give someone the opportunity to pay to use apps is ridiculous.
Unconfigured Ad
Collapse
X
-
To be fair, that $5k (if that is what the cost of the mid-tier subscription is) appears to include two additional features.Originally posted by thermophile View PostI'm not surprised that they moved to subscription. But an annual $5000 buy in to give someone the opportunity to pay to use apps is ridiculous.
Whether "Multi-user access" and 8hr of bioinformatics professional services support is worth $5K, is open to debate
If you don't have any local IT infrastructure then that may be your sole option.
Comment
-
-
Software release note for 2.18 has this listed as "known issue"Originally posted by kcchan View PostThat issue still hasn't been fixed as of the the most recent 2.18 update.
“N” is incorrectly allowed as an index sequence character in the sample sheet. When used, this will cause a mismatch for any sequence character other than “N”.
Comment
-
-
Does that apply to all apps or just the third party ones that we would normally be paying for? Right now, it looks like the usual basic analyses I'm used to running are still accessible from a basic account, but I think my account is still on a trial basis from the changeover.Originally posted by kcchan View PostI would imagine some of the third party developers aren't too happy either since their apps are now stuck behind a paywall.
Comment
-
-
Wait, so we can't even do FastQC with a free account? I was able to run it, but like I said yesterday, my account is still in trial mode. Are you just trying to use the Illumina/BaseSpace Labs 16s metagenomics app? I'm not hopeful for my Amplicon DS analyses, then....Originally posted by thermophile View PostI can select a sample, launch FastQC or 16S metagenomics, but then I don't have the start button
Comment
-
-
Jessica, I can't run any apps at all. My understanding is that every new account gets a 30day trial so I guess you could just make a new email and account every month to continue using the apps.Microbial ecologist, running a sequencing core. I have lots of strong opinions on how to survey communities, pretty sure some are even correct.
Comment
-
-
While that may work short term, it may land you on Illumina's blacklist (if they watch for what IP's the accounts are logging in from).Originally posted by thermophile View PostJessica, I can't run any apps at all. My understanding is that every new account gets a 30day trial so I guess you could just make a new email and account every month to continue using the apps.
Small cores may need to adjust their prices (and account for $5K subscription) if they find BaseSpace indispensable for daily business.
Comment
-
-
True. I'm likely going to go back to ignoring the basespace apps and use it just for fastq distribution which is still currently feasible for my miseq only core on a free account.Originally posted by GenoMax View PostWhile that may work short term, it may land you on Illumina's blacklist (if they watch for what IP's the accounts are logging in from).
Small cores may need to adjust their prices (and account for $5K subscription) if they find BaseSpace indispensable for daily business.Microbial ecologist, running a sequencing core. I have lots of strong opinions on how to survey communities, pretty sure some are even correct.
Comment
-
Latest Articles
Collapse
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
18 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|
||
|
Started by SEQadmin2, 07-13-2026, 10:26 AM
|
0 responses
33 views
0 reactions
|
Last Post
by SEQadmin2
07-13-2026, 10:26 AM
|
||
|
Started by SEQadmin2, 07-09-2026, 10:04 AM
|
0 responses
44 views
0 reactions
|
Last Post
by SEQadmin2
07-09-2026, 10:04 AM
|
||
|
Started by SEQadmin2, 07-08-2026, 10:08 AM
|
0 responses
30 views
0 reactions
|
Last Post
by SEQadmin2
07-08-2026, 10:08 AM
|
Comment